UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035776
Receipt number R000040751
Scientific Title A study to examine the effects of Lactobacillus salivarius L55 intake on relief from eye and nasal discomfort.
Date of disclosure of the study information 2019/02/15
Last modified on 2021/02/16 19:22:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to examine the effects of Lactobacillus salivarius L55 intake on relief from eye and nasal discomfort.

Acronym

A study to examine the effects of Lactobacillus salivarius L55 intake on relief from eye and nasal discomfort.

Scientific Title

A study to examine the effects of Lactobacillus salivarius L55 intake on relief from eye and nasal discomfort.

Scientific Title:Acronym

A study to examine the effects of Lactobacillus salivarius L55 intake on relief from eye and nasal discomfort.

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess the efficacy and safety of test food for eye and nasal discomfort after 12-week ingestion of test food in healthy Japanese males and females (20 to 64 years old) who do not need drug treatment but complain of eye and nasal discomfort (such as sneezing, a blocked or runny nose, and itchy eyes) in their everyday lives.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Eye and nasal symptom questionnaire ,The Japanese Rhinoconjunctivitis Quality of Life Questionnaire version 2002 (JRQLQ No1)

Key secondary outcomes

Assessment of the nasal cavity (mucosal swelling and mucosal color of the inferior turbinate, serous fluid volume, and characteristics of nasal discharge)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Drink fermented milk containing only Lactobacillus salivarius L55 once daily after a meal.

Interventions/Control_2

Drink placebo once daily after a meal.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. 20 to 64 years old (at the time of submission of an informed consent document).
2. Japanese males and females.
3. Those who have symptoms, such as itchy eyes and a blocked or runny nose, in their everyday lives, but those who are healthy and have no chronic somatic disorders.
4. Body mass index (BMI) of less than 30 kg/m2
5. Non-smokers (which include electronic cigarette users)
6. Those who can collaborate on 12-week ingestion of test food.
7. Those who have a device available for an electronic diary and who can input their own data into the device.
8. Those who receive a full explanation of the purpose and content of this clinical trial, those who desire and voluntarily request to participate in this clinical trial with a full understanding of its explanation, those who have the capability to consent, and those who can give their written informed consent.
9. Those who were judged as non-diseased individuals by the principal investigator or a sub-investigator and those who were determined to be suitable for participation in this clinical trial.

Key exclusion criteria

1. Those who were categized into "severe" or "the most severe" according to the classification of allergic rhinitis based on severity of symptoms.
2. Those who have acute rhinitis, sinusitis, nasal polyp, hypertrophic rhinitis, and deviated septum.
3. Those who have bronchial asthma as a complication.
4. Those who have the serious disorders of the liver, heart, kidney, respiratory system, endocrine, and metabolism.
5. Those who currently receive or have previously received allergen immunotherapy.
6. Those who currently take some kind of medication for therapeutic purposes.
7. Those with a past and current medical history of drug or food allergy.
8. Those who ingest Lactobacillus preparations, Lactobacillus supplements, yogurts, foods for specified health use, and foods with function claims on a daily basis (however, at the time of submission of an informed consent document, those who can stop ingesting foods listed above during the study period are excluded).
9. Those who are currently pregnant or breastfeeding or those who desire a pregnancy during the study period.
10. Those who have experienced a feeling sick or health deterioration due to blood sampling.
11. Those who have diarrhea by dairy products and those who have lactose intolerance.
12. Those who participated in another clinical trial within one month before our screening test and those who took an active ingredient provided in the clinical trial.
13. Those who may undergo lifestyle changes (such as a long trip) during the study period.
14. Those who were determined by the principal investigator to be unsuitable for participation in this clinical trial.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Shoji
Middle name
Last name Nakamura

Organization

OHAYO DAIRY PRODUCTS CO., LTD.

Division name

Fundamental laboratory, Research and development 1, Research and development division

Zip code

703-8225

Address

565 Kojita, Naka-ku, Okayama-City, Okayama, Japan

TEL

086-279-1238

Email

s_nakamura@ohayo-milk.com


Public contact

Name of contact person

1st name Naomi
Middle name
Last name Yuzawa

Organization

IMEQRD Co., Ltd

Division name

Sales department

Zip code

104-0061

Address

6-2-1 Ginza Chuo-ku Tokyo Japan

TEL

03-6704-5968

Homepage URL


Email

n-yuzawa@imeqrd.co.jp


Sponsor or person

Institute

IMEQRD Co., Ltd

Institute

Department

Personal name



Funding Source

Organization

OHAYO DAIRY PRODUCTS CO., LTD.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Suda Clinic institutional review board

Address

2-8-14,Takadanobaba,Shinjyuku,Tokyo

Tel

03-6704-5968

Email

n-yuzawa@imeqrd.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 02 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 01 Month 11 Day

Date of IRB

2019 Year 01 Month 30 Day

Anticipated trial start date

2019 Year 03 Month 22 Day

Last follow-up date

2019 Year 07 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 02 Month 05 Day

Last modified on

2021 Year 02 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040751


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name